98. Eosinophilic gastrointestinal disease Clinical trials / Disease details
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02098473 (ClinicalTrials.gov) | August 31, 2014 | 25/3/2014 | Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis | A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: RPC4046;Drug: Placebo | Celgene | NULL | Completed | 18 Years | 65 Years | All | 100 | Phase 2 | United States;Canada;Switzerland |